AdaptHealth Corp. (NASDAQ:AHCO) Shares Acquired by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC grew its stake in shares of AdaptHealth Corp. (NASDAQ:AHCO - Free Report) by 6,044.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,775 shares of the company's stock after acquiring an additional 34,209 shares during the quarter. Tower Research Capital LLC TRC's holdings in AdaptHealth were worth $331,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the stock. Barclays PLC boosted its holdings in AdaptHealth by 361.3% during the third quarter. Barclays PLC now owns 181,240 shares of the company's stock worth $2,034,000 after buying an additional 141,949 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of AdaptHealth by 20.2% in the third quarter. Franklin Resources Inc. now owns 65,601 shares of the company's stock valued at $737,000 after purchasing an additional 11,037 shares during the last quarter. Principal Financial Group Inc. lifted its position in AdaptHealth by 39.7% during the third quarter. Principal Financial Group Inc. now owns 543,744 shares of the company's stock worth $6,106,000 after buying an additional 154,434 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in AdaptHealth by 73.2% during the third quarter. JPMorgan Chase & Co. now owns 191,833 shares of the company's stock worth $2,154,000 after buying an additional 81,097 shares during the last quarter. Finally, Harbor Capital Advisors Inc. grew its holdings in AdaptHealth by 5.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 474,722 shares of the company's stock valued at $4,519,000 after buying an additional 24,882 shares in the last quarter. Institutional investors and hedge funds own 82.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Robert W. Baird upped their price objective on shares of AdaptHealth from $14.00 to $16.00 and gave the company an "outperform" rating in a report on Thursday, February 27th. Canaccord Genuity Group lifted their price target on shares of AdaptHealth from $13.00 to $14.00 and gave the company a "buy" rating in a research report on Wednesday, February 26th. UBS Group lowered their price objective on AdaptHealth from $12.00 to $11.00 and set a "buy" rating for the company in a research report on Thursday, February 13th. Royal Bank of Canada lifted their target price on AdaptHealth from $11.00 to $14.00 and gave the company an "outperform" rating in a research report on Wednesday, February 26th. Finally, Truist Financial increased their price target on AdaptHealth from $12.00 to $14.00 and gave the stock a "buy" rating in a report on Wednesday, February 26th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $13.80.

AdaptHealth Stock Performance

NASDAQ AHCO traded down $0.28 during trading hours on Wednesday, hitting $8.57. The company had a trading volume of 229,352 shares, compared to its average volume of 1,274,798. The business has a 50 day moving average of $9.44 and a 200-day moving average of $9.78. The company has a market cap of $1.16 billion, a PE ratio of -5.19, a price-to-earnings-growth ratio of 1.08 and a beta of 1.64. AdaptHealth Corp. has a 1-year low of $7.11 and a 1-year high of $11.90. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.00 and a current ratio of 1.24.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.